Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma in the Treatment of Covid-19
NCT04730401Phase 2Unknown
- Sponsor
- Helsinki University Hospital
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Helsinki University Hospital. Primary endpoints: Serious Adverse Events at 6 hours and Rate of intubation or systemic corticosteroids initiation at 21 days. Status: unknown.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04730401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04730401.